EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial

Ranibizumab mit Luseogliflozin bei Typ-2-Diabetes und diabetischem Makulaödem: randomisierte klinische Studie

Ryoichi Ishibashi iD, Yoko Takatsuna, Masaya Koshizaka iD, Tomoaki Tatsumi, Sho Takahashi, Kengo Nagashima iD, Ko Ishikawa, Tomomi Kaiho, Noriko Asaumi, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote iD und 1 weitere

Diabetes, Obesity and Metabolism · 2025-05 · 27 (5) · 2473-2484

DOI: 10.1111/dom.16244 ↗

Auf einen Blick

Bei 60 Patient:innen mit diabetischem Makulaödem zeigte Luseogliflozin im Vergleich zu Glimepirid keine geringere Zahl an Ranibizumab-Injektionen im Zielauge; im Fellow Eye waren weniger Injektionen nötig.

Fragestellung

Wirksamkeit von SGLT2-Inhibitoren bei diabetischem Makulaödem im Vergleich zu Sulfonylharnstoffen.

Methode

Multizentrische randomisierte offene Studie mit 60 Patient:innen; Randomisierung zu Luseogliflozin oder Glimepirid; Ranibizumab initial im Zielauge, weitere Gaben nach Protokoll.

Ergebnisse

Im Zielauge waren die Injektionszahlen ähnlich (3,9 ± 0,7 vs. 4,7 ± 0,7; p = 0,36). Nach der vierten Injektion waren die Re-Administrationsraten im SGLT2i-Arm niedriger (p = 0,030; Hazard Ratio 0,45; 95 %-KI 0,22–0,92). Im Fellow Eye weniger Injektionen (1,3 ± 0,6 vs. 3,4 ± 0,8; p = 0,016).

Schlussfolgerung der Autor:innen

Obwohl die Gesamtzahl der Anti-VEGF-Injektionen im Zielauge keinen signifikanten Unterschied zeigte, sprachen einige Patient:innen günstiger auf SGLT2i an und benötigten weniger Injektionen.

Kernaussagen

  • Zielauge: ähnliche Injektionszahl unter SGLT2i und SU
  • Nach der vierten Injektion niedrigere Re-Administrationsrate unter SGLT2i
  • Fellow Eye: weniger Injektionen und CRT-Reduktion unter SGLT2i

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 11.02.2025. Verfasst von Ryoichi Ishibashi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Kisarazu, Japan. Hauptthemen laut MEDLINE: Macular Edema, Ranibizumab, Diabetes Mellitus, Type 2, Diabetic Retinopathy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Taisho Pharmaceutical Co., Ltd.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Anti‐vascular endothelial growth factor (VEGF) therapy is the standard treatment for diabetic macular oedema (DMO); however, unmet needs remain. This study aimed to assess the effectiveness of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in treating DMO. Materials and Methods This multicentre randomised open‐label trial included 60 patients with DMO who were eligible for anti‐VEGF therapy. Patients were randomised to receive luseogliflozin or glimepiride. Ranibizumab was administered initially to the target eye, with additional doses per protocol. The number of ranibizumab doses up to week 48, and re‐admission rates were evaluated. Fellow eye injections were also assessed.

Results

Sixty participants, mostly with diabetic retinopathy and half previously treated with anti‐VEGF therapy, were included. SGLT2i and sulfonylurea (SU) groups achieved equivalent glycated haemoglobin, central retinal thickness (CRT), and best‐corrected visual acuity improvements. Injection frequency for the target eye was similar between groups (SGLT2i vs. SU: 3.9 ± 0.7 vs. 4.7 ± 0.7 times, p = 0.36). Re‐administration rates were decreased significantly after the fourth injection in the SGLT2i group ( p = 0.030, hazard ratio: 0.45, 95% confidence interval: 0.22–0.92). Fellow eyes in the SGLT2i group showed significant CRT reduction and fewer injections compared with those in the SU group (1.3 ± 0.6 vs. 3.4 ± 0.8, p = 0.016).

Conclusions

Although the overall number of anti‐VEGF injections in the target eye showed no significant difference, some patients responded favourably to SGLT2i and required fewer injections. The reduction in fellow eye injections suggests SGLT2i's efficacy in treating early‐stage DMO. Trial Registration University Hospital Medical Information Network Clinical Trial Registry (UMIN000033961); Japan Registry of Clinical Trials (jRCTs031180210).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaRanibizumabDiabetes Mellitus, Type 2Diabetic RetinopathySodium-Glucose Transporter 2 InhibitorsSorbitolAngiogenesis InhibitorsHumansMaleFemaleMiddle AgedAgedSulfonylurea CompoundsDrug Therapy, CombinationTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityIntravitreal InjectionsGlycated HemoglobinHypoglycemic Agents

Stichwörter der Autor:innen

SGLT2 inhibitordiabetic macular oedemarandomised trialtype 2 diabetes

Substanzen

RanibizumabSodium-Glucose Transporter 2 InhibitorsSulfonylurea Compounds1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitolSorbitolAngiogenesis InhibitorsglimepirideVascular Endothelial Growth Factor AGlycated HemoglobinHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Kisarazu, Japan.
  • Department of Endocrinology, Haematology and Gerontology, Chiba University Graduate School of Medicine, Japan.
  • Department of Ophthalmology, Chiba Rosai Hospital, Japan.
  • Department of Ophthalmology and Vision Science, Chiba University Graduate School of Medicine, Japan.
  • Department of Nutrition and Metabolic Medicine, Center for Preventive Medical Science, Chiba University, Japan.
  • Center for Research Promotion, The Jikei University School of Medicine, Japan.

ORCID-Profile: Ryoichi Ishibashi, Masaya Koshizaka, Kengo Nagashima, Koutaro Yokote

Förderung

  • Taisho Pharmaceutical Co., Ltd

Zitieren

APA

Ishibashi, R., Takatsuna, Y., Koshizaka, M., Tatsumi, T., Takahashi, S., Nagashima, K., Ishikawa, K., Kaiho, T., Asaumi, N., Baba, T., Yamamoto, S., Yokote, K., & COMET Trial investigators (2025). Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial. Diabetes, Obesity and Metabolism, 27(5), 2473-2484. https://doi.org/10.1111/dom.16244

Vancouver

Ishibashi R, Takatsuna Y, Koshizaka M, Tatsumi T, Takahashi S, Nagashima K, et al. Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial. Diabetes, Obesity and Metabolism. 2025;27(5):2473-2484. doi:10.1111/dom.16244

BibTeX
@article{Ishibashi2025,
  author = {Ishibashi, Ryoichi and Takatsuna, Yoko and Koshizaka, Masaya and Tatsumi, Tomoaki and Takahashi, Sho and Nagashima, Kengo and Ishikawa, Ko and Kaiho, Tomomi and Asaumi, Noriko and Baba, Takayuki and Yamamoto, Shuichi and Yokote, Koutaro and COMET Trial investigators, COMET Trial investigators},
  title = {Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {5},
  pages = {2473--2484},
  doi = {10.1111/dom.16244}
}
Kostenlos starten →